Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 19:
20. The Ligand Drug Conjugate compound of claim 1, wherein the first optional Stretcher Unit (A), or a subunit thereof, is present and has the structure of formula (3a) or formula (4a):, or a pharmaceutically acceptable salt thereof, wherein
subscript e and f are independently 0 or 1,
G is hydrogen, optionally substituted C1-C6 alkyl, —OH, —ORPR, —CO2H, CO2RPR, wherein RPR is a suitable protecting, or
G is —N(RPR)(RPR), wherein RPR are independently a protecting group or RPR together form a suitable protecting group, or
G is —N(R45)(R46), wherein one of R45, R46 is hydrogen or RPR, wherein RPR is a suitable protecting group, and the other is hydrogen or optionally substituted C1-C6 alkyl;
wherein R38 is hydrogen or optionally substituted C1-C6 alkyl;
R39, R40, R41, R42, R43, R44 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, and optionally substituted heteroaryl, or R39, R40 together with the carbon to which both are attached, and R41 to R44 are as defined herein, or
R41, R42 together with the carbon atom to which both are attached define a C3-C6 carbocyclo, and R39, R43 and R44 are as defined herein,
or R43, R44 together with the carbon atom to which both are attached define a C3-C6 cycloalkyl, and R39 to R42 are as defined herein,
or R40 and R41, or R40 and R43, or R41 and R43 to together with the carbon atoms to which they are attached and the atoms intervening between those carbon atoms define a C5-C6 carbocyclo, and R39, R44 and the remainder of R40-R43 are as defined herein, or
A or a subunit thereof is an alpha-amino or beta-amino acid residue.